Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 215.59K shares, a 326.50% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 753.08K shares, a 22576.15% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 368.53K shares, a 953.99% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 204.75K shares, a 1340.69% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 627.15K shares, a 654.50% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 83.12K shares, a 2870.73% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.80K shares.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 215.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 1.54M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 753.08K shares 10-Q · filed 2026-05-05 | 1.38M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 368.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 627.15K shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 204.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 293.59K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 50.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 103.05K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 3.32K shares 10-Q · filed 2025-05-12 | 56.01K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 34.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 83.12K shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 14.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 48.16K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 3.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 30.43K shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 2.80K shares 10-K · filed 2024-03-21 |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-23 | |
| 2021-12-31 | 422.00K shares 10-K · filed 2022-03-08 | |
| 2020-12-31 | 447.40K shares 10-K · filed 2021-03-03 | |
| 2019-12-31 | 294.31K shares 10-K · filed 2020-03-03 | |
| 2018-12-31 | 4.15K shares 10-K · filed 2019-03-19 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-19 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |